TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?

Tempus AI (TEM) posted robust Q2 results, with 89.6% revenue growth and a 158.3% surge in gross profit, leading to a second upward revision of its 2025 sales guidance to $1.26 billion. Adjusted EBITDA also improved sequentially, with positive EBITDA projected for 2025. This strong performance, which has fueled a 137.6% YTD stock surge, is driven by strategic acquisitions like Paige, Deep 6 AI, and Ambry Genetics, expanding its AI-driven healthcare offerings and data reach, alongside significant innovation. However, the company faces challenges including reimbursement hurdles for certain product segments and currently trades at a premium valuation, tempering the outlook despite strong fundamentals and a solid balance sheet.

Analysis

Tempus AI demonstrated significant operational momentum in its second-quarter results, posting an 89.6% year-over-year revenue increase and a 158.3% surge in gross profit. This performance prompted the company to raise its full-year 2025 revenue guidance to $1.26 billion, implying an 82% annual growth rate. The path to profitability is also improving, evidenced by the adjusted EBITDA loss narrowing sequentially from negative $16 million to negative $5.6 million, with the company now projecting a positive adjusted EBITDA of $5 million in 2025. Growth is being fueled by strong segmental performance, including a 115% increase in Genomics sales and a 35.7% rise in Data and Services revenues, bolstered by strategic acquisitions like Paige and Deep 6 AI which have expanded its dataset to 30 million patient records. However, this aggressive growth story is tempered by two key factors: a significant valuation premium and a critical operational headwind. The stock's 137.6% year-to-date surge has pushed its forward five-year price-to-sales ratio to 9.41x, well above the industry average of 5.84x. Furthermore, the lack of reimbursement for key product lines, including its minimal residual disease (MRD) portfolio, is currently gating volume growth and margin expansion, posing a material risk to its outlook despite a strong balance sheet with $293 million in cash and no current debt.

Key Decisions for Investors

• Given the exceptional top-line growth and improving EBITDA trajectory, existing investors should consider holding their positions to capitalize on the company's strong execution and market leadership, as reflected in its 137.6% YTD outperformance.
• Prospective investors should be cautious of the elevated valuation, with a forward P/S of 9.41X representing a significant premium to peers, and may want to await a more attractive entry point or a resolution of key risks.
• Investors must closely monitor developments regarding payer reimbursement for Tempus AI's MRD and TRM portfolios, as securing coverage is a critical catalyst for future revenue scale and margin expansion.
• Note that while 2025 sales estimates are rising, consensus loss-per-share estimates have deteriorated by 3% in the past month, suggesting analyst caution on near-term profitability despite the strong revenue narrative.